CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 177 enrolled
Drug / intervention
Tapentadol +1 moredrug
Likely dose
Tapentadol 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01435577
NCT01435577Phase 2Completed

A Randomized, Double-blind, Placebo-controlled Parallel Group, Multicenter Trial to Evaluate the Efficacy and Safety of Multiple Dose Administration of an Intravenous Formulation of Tapentadol in the Treatment of Acute Pain Following Bunionectomy.

Grünenthal GmbH·interventional·Posted Sep 16, 2011·Updated Oct 28, 2019

In Brief

A Phase 2 clinical trial evaluating Tapentadol and Matching Placebo for Bunion and Pain. Completed, enrolled 177 participants across 1 site.

Detailed Summary

The purpose of this trial is to established the safety and efficacy of multiple dose treatment with tapentadol IV in an adult population with moderate to severe pain following bunionectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBunion, Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 16, 2011
Enrollment StartSep 1, 2011
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.8 years ago

Interventions

Tapentadoldrug

30 mg per administration, maximum 12 administrations over 48 hours

Matching Placebodrug

Maximum 12 administrations over 48 hours